Company Overview of KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. The company’s product candidates include KB004, which is in a Phase II clinical trial for the treatment of myelodysplastic syndrome and myelofibrosis; and KB003 that completed Phase II clinical trial to treat chronic myelomonocytic leukemia, an orphan oncology indication. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is headquartered in South San Francisco, California.
260 East Grand Avenue
South San Francisco, CA 94080
Founded in 2000
Key Executives for KaloBios Pharmaceuticals, Inc.
Chief Scientific Officer
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2013.
KaloBios Pharmaceuticals, Inc. Key Developments
Kalobios Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014
Mar 16 15
KaloBios Pharmaceuticals, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported contract revenue of $44,000 a year ago. Loss from operations was $36,718,000 compared to $40,909,000 a year ago. Net loss was $37,998,000 or $1.15 basic and diluted per share compared to $41,948,000 or $1.73 basic and diluted per share a year ago.
KaloBios Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
Mar 16 15
KaloBios Pharmaceuticals, Inc. filed its 10-K on Mar 16, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
KaloBios Pharmaceuticals Receives Non-Compliance Notice From NASDAQ
Feb 23 15
On February 20, 2015, KaloBios Pharmaceuticals, Inc. received a deficiency letter from The NASDAQ Stock Market LLC (NASDAQ) indicating that, based on the Company’s closing bid price for the last 30 consecutive business days, the Company does not comply with the minimum bid price requirement of $1.00 per share, as set forth in NASDAQ Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of the Company’s common stock on The NASDAQ Global Market. In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until August 19, 2015, to regain compliance with the minimum closing bid price requirement for continued listing. In order to regain compliance, the minimum closing bid price per share of the Company’s common stock must be at least $1.00 for a minimum of ten consecutive business days. In the event the Company does not regain compliance by August 19, 2015, the Company may be afforded an additional 180-day compliance period, provided it demonstrates that it meets all other applicable standards for initial listing on The Nasdaq Global Market (except the bid price requirement), and provides written notice of its intention to cure the minimum bid price deficiency during the second grace period, by effecting a reverse stock split, if necessary. If the Company fails to regain compliance after the second grace period, the Company’s stock will be subject to delisting by NASDAQ. The Company is considering actions that it may take in response to this notification in order to regain compliance with the continued listing requirements.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|